<DOC>
	<DOCNO>NCT01595828</DOCNO>
	<brief_summary>The purpose study examine detail acute chronic effect pitavastatin plasma lipid transport atheroma biomarkers patient elevate risk premature development atherosclerosis ( CAPITAIN ) .</brief_summary>
	<brief_title>Effects Pitavastatin Monocyte , Endothelial Dysfunction HDL-C Subjects With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Patients metabolic syndrome Patients LDLC &gt; 130mg/dL Eligible , able participate give informed consent Body Mass Index &gt; 35 kg/m2 LDLC &gt; 190mg/dL Fasting triglyceride &gt; 400 mg/dL Diabetes mellitus ( fast glucose &gt; 7 mmol/L ) take diabetic therapy Uncontrolled hypertension ( Systolic Blood Pressure &gt; = 140 mmHg Diastolic Blood Pressure &gt; = 90mmHg ) Any condition cause secondary dyslipidaemia increase risk statin therapy ALAT ASAT &gt; 3 x ULRR Impaired renal function ( Serum Creatinine &gt; 1.5 x ULRR eGFR &lt; 60 mL/min ) History muscle disease unexplained elevation ( &gt; 3 x ULRR ) serum creatine kinase Evidence symptomatic heart failure ( NYHA class III IV ) Current recent user supplement medication know alter lipid metabolism</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>